肠道微生物群代谢物:阿尔茨海默病的潜在治疗点?
Shanshan Zhang1, Jing Lu2, Ziqi Jin1
1The School to Changchun University of Chinese Medicine, Changchun, China.
Frontiers in pharmacology
|October 2, 2024
概括
肠道微生物组通过肠-大脑轴影响阿尔茨海默病 (AD) 病理学. 通过生活方式和向益生菌调节肠道微生物群,为AD提供了一个有希望的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 新兴研究表明,肠道微生物组与AD的潜在病理之间存在联系.
研究的目的:
- 审查针对肠道微生物群的机制和干预措施,以对阿尔茨海默氏病进行管理.
- 探索肠-大脑轴,微生物代谢物和AD的微生物群调节疗法.
主要方法:
- 关于阿尔茨海默病,肠-大脑轴和微生物代谢物的当前研究的全面审查.
- 分析治疗策略,包括益生菌,便微生物群移植和抗生素.
主要成果:
- 肠道微生物群与大脑双向通信,影响AD病变的发生.
- 微生物代谢物 (脂,脂) 调节AD的关键机制,如粉样蛋白代谢,酸酸化和神经炎症.
- 针对肠道微生物群的干预措施显示出在治疗阿尔茨海默症方面具有潜力.
结论:
- 肠道微生物是改善AD症状的肠-大脑轴的关键目标.
- 需要进一步的多学科研究来充分阐明分子机制.
- 健康的生活方式,向益生菌和其他干预措施的结合可以恢复AD治疗的肠道平衡.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451


